Scinai Immunotherapeutics Ltd.

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: 𝐖𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐎𝐮𝐫 𝐅𝐢𝐫𝐬𝐭 𝐔.𝐒. 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 – Serpin Pharma! 𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐚𝐭 𝐒𝐞𝐫𝐩𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚, 𝐚 𝐕𝐢𝐫𝐠𝐢𝐧𝐢𝐚-𝐛𝐚𝐬𝐞𝐝 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐲, 𝐡𝐚𝐬 𝐜𝐡𝐨𝐬𝐞𝐧 𝐒𝐜𝐢𝐧𝐚𝐢 𝐁𝐢𝐨𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐈𝐧𝐜. 𝐛𝐨𝐮𝐭𝐢𝐪𝐮𝐞 𝐂𝐃𝐌𝐎 𝐚𝐬 𝐭𝐡𝐞𝐢𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫 𝐟𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠. Serpin Pharma is at the forefront of innovation, developing targeted therapeutics to enhance the body’s natural immune response. Their lead asset, SP16, is a novel peptide drug derived from human alpha-1-antitrypsin, targeting the LRP1 receptor to reduce inflammation and restore immune balance. SP16 has demonstrated significant potential in treating inflammatory conditions, such as: ✨ Acute myocardial infarction ✨ Chemotherapy-induced peripheral neuropathy ✨ Acute kidney injury The company has secured significant funding, including a $2 million NCI grant and a $900,000 BIRD Foundation grant, to advance clinical trials for SP16 and its variants With 13 approved patents, $2.9M in secured funding, and collaborations with top research institutions, Serpin Pharma is poised to potentially transform the treatment landscape for inflammatory diseases. Dr. Cohava Gelber, PhD, MBA, CEO, Founder, and Chairperson of Serpin Pharma, shared: "𝑊𝑒 𝑎𝑟𝑒 𝑒𝑥𝑐𝑖𝑡𝑒𝑑 𝑡𝑜 𝑏𝑒 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑤𝑖𝑡ℎ 𝑆𝑐𝑖𝑛𝑎𝑖 𝐵𝑖𝑜𝑠𝑒𝑟𝑣𝑖𝑐𝑒𝑠 𝐼𝑛𝑐. 𝑊𝑒 𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 𝑆𝑐𝑖𝑛𝑎𝑖 𝑎𝑠 𝑎 𝑝𝑎𝑟𝑡𝑛𝑒𝑟 𝑓𝑟𝑜𝑚 𝑚𝑎𝑛𝑦 𝐶𝐷𝑀𝑂𝑠 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑡ℎ𝑒 𝑐𝑜𝑚𝑝𝑎𝑛𝑦'𝑠 𝑐𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑠𝑡𝑟𝑜𝑛𝑔 𝑠𝑐𝑖𝑒𝑛𝑡𝑖𝑓𝑖𝑐 𝑒𝑥𝑝𝑒𝑟𝑡𝑖𝑠𝑒 𝑜𝑓 𝑖𝑡𝑠 𝑡𝑒𝑎𝑚 𝑚𝑒𝑚𝑏𝑒𝑟𝑠." 𝐓𝐡𝐢𝐬 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐫𝐞𝐟𝐥𝐞𝐜𝐭𝐬 𝐨𝐮𝐫 𝐝𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬. 𝑾𝒆𝒍𝒄𝒐𝒎𝒆, 𝑺𝒆𝒓𝒑𝒊𝒏 𝑷𝒉𝒂𝒓𝒎𝒂—𝒘𝒆’𝒓𝒆 𝒑𝒓𝒐𝒖𝒅 𝒕𝒐 𝒔𝒖𝒑𝒑𝒐𝒓𝒕 𝒚𝒐𝒖𝒓 𝒋𝒐𝒖𝒓𝒏𝒆𝒚 𝒂𝒔 𝒐𝒖𝒓 𝒇𝒊𝒓𝒔𝒕 𝑼.𝑺. 𝒄𝒍𝒊𝒆𝒏𝒕! 🌟 #ScinaiBioservices #CDMO #Innovation #Biopharma #Partnerships #DrugDevelopment Amir Reichman Elad Mark Tehila Sonnenfeld

𝐒𝐜𝐢𝐧𝐚𝐢 𝐁𝐢𝐨𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐔.𝐒.! 🇺🇸  🔊We’re excited to announce the launch of Scinai Bioservices Inc., our Delaware-based subsidiary, bringing top-tier #CDMO services to U.S. early-stage biotech companies. 👉 𝐀 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧: Building on the success of our Jerusalem CDMO unit—1,850 m² (~20,000 ft²) of cGMP-compliant clean rooms and labs—we’re now expanding to the U.S. market. Since launching, we’ve supported nine biotech companies with services like process development, scale-up, analytical methods, and clinical manufacturing, including liposomal drug development with Ayana Pharma. 📍 𝐒𝐞𝐢𝐳𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 🇺🇸: The U.S. demand for CDMO services is surging, driven by the complexity of biologics and rapid drug approvals. Scinai Bioservices Inc. offers boutique, high-quality solutions while remaining compliant with the BIOSECURE Act, enabling U.S. biotech startups to access federal funding without foreign partnership restrictions. 🤝𝐊𝐢𝐜𝐤𝐢𝐧𝐠 𝐎𝐟𝐟 𝐰𝐢𝐭𝐡 Serpin Pharma: We’re proud to support their clinical manufacturing needs as our first U.S. client! CEO Amir Reichman: “𝑂𝑢𝑟 𝑈.𝑆. 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ𝑒𝑛𝑠 𝑜𝑢𝑟 𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑡𝑜 𝑚𝑒𝑒𝑡 𝑚𝑎𝑟𝑘𝑒𝑡 𝑑𝑒𝑚𝑎𝑛𝑑 𝑤ℎ𝑖𝑙𝑒 𝑑𝑟𝑖𝑣𝑖𝑛𝑔 𝑔𝑟𝑜𝑤𝑡ℎ 𝑎𝑛𝑑 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝐶𝐷𝑀𝑂 𝑠𝑒𝑐𝑡𝑜𝑟.” #ScinaiBioservices #CDMO #BiotechInnovation #USExpansion #LifeScience Elad Mark Dalit Fischer

Scinai Immunotherapeutics Ltd. 𝐢𝐬 𝐇𝐞𝐚𝐝𝐢𝐧𝐠 𝐭𝐨 𝐉.𝐏. 𝐌𝐨𝐫𝐠𝐚𝐧 𝟐𝟎𝟐𝟓! The Scinai team is thrilled to attend the J.P. Morgan Annual Healthcare Conference this January! 𝐃𝐨𝐧’𝐭 𝐦𝐢𝐬𝐬 𝐭𝐡𝐞 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐜𝐨𝐧𝐧𝐞𝐜𝐭 𝐰𝐢𝐭𝐡 Amir Reichman 𝐒𝐜𝐢𝐧𝐚𝐢’𝐬 𝐂𝐄𝐎, 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐞𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬. Here’s what we’ll be sharing: 📍 Our Pipeline Potential: Learn about our innovative Anti-IL-17A/F sdAb, designed to address the unmet needs of mild to moderate plaque psoriasis patients. 📈 Unique Investment Opportunity: Discover why Scinai presents a compelling case for investors, with a unique entry point and promising developments on the horizon. 📍 Recent Business Milestones: Hear about our R&D and CDMO achievements, including key commercial wins and geographic expansion. 👉 Enhanced Expertise: Learn more about our strengthened advisory board featuring top KOLs and industry leaders who bring unparalleled insights to our mission. 🤝 Let’s Meet! Contact us at ir@scinai.com to schedule a meeting and dive into what makes Scinai a game-changer in I&I treatment. #JPM2025 #ScinaiImmunotherapeutics #BiotechInnovation #InvestmentOpportunities #pharmapartnership #druglicensing

Huge congratulations to Dr. Jonathan Sadeh, M.D., M.Sc., a Scinai Immunotherapeutics Ltd. Scientific Advisory Board member, on his recent appointment as Chief Scientific Officer and Chief Medical Officer of Bausch Health Companies Inc. We are proud to have such a high-caliber talent advising our R&D team and board of directors and wish Dr. Sadeh the best of success in his new role! Amir Reichman #advisoryboard #innovation #biotech #newappointment

#Announcement #AdvisoryBoard We are thrilled to announce that Professor Michael Schön, Director of Dermatology and Venereology at the prestigious University Medical Center Göttingen (UMG), has joined Scinai Immunotherapeutics Ltd. Scientific Advisory Board! Prof. Schön brings unparalleled expertise in immunotherapy and dermatology, strengthening our mission to develop groundbreaking treatments. Reflecting on his new role, Prof. Schön shared: "Scinai’s innovative approach to immunotherapy holds incredible potential to address unmet medical needs. I am eager to contribute to advancing their pipeline and translating innovative science into transformative therapies." Scinai's CEO, Amir Reichman, emphasized the significance of this collaboration: "Having Prof. Schön on our Scientific Advisory Board is a testament to the strength of Scinai’s scientific foundation and our commitment to advancing cutting-edge immunotherapies. His insights will be invaluable as we progress our pipeline." This partnership underscores Scinai's dedication to pioneering solutions for unmet medical needs. Stay tuned as we continue breaking new ground in immunotherapy! #Welcomeonboard #InnovationInImmunotherapy #VHH #sdAB #Dermatology #ScientificAdvisoryBoard #Scinai

𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐚 𝐧𝐞𝐰 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 Hopec Pharma 𝐚𝐧𝐝 𝐰𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐡𝐞𝐦 𝐭𝐨 Scinai Immunotherapeutics Ltd. 𝐟𝐚𝐦𝐢𝐥𝐲. Hopec is a visionary biopharmaceutical company advancing Non-Muscle Invasive Bladder Cancer (NMIBC) treatment with a groundbreaking UPEC-FimON immunotherapy. 📍Our services for Hopec focus, first and foremost, on manufacturing their innovative immunotherapy medicine with the highest standards in Scinai Immunotherapeutics Ltd. state-of-the-art GMP-certified facilities. 👉 Beyond this, we provide comprehensive project management, strategic alignment in creating an exact Chemistry, Manufacturing, and Controls (CMC) file, and essential support for Helsinki committee submissions and clinical trial preparations, ensuring a seamless process from development to patient delivery.   "𝑊𝑒 𝑐ℎ𝑜𝑠𝑒 𝑆𝑐𝑖𝑛𝑎𝑖 𝑛𝑜𝑡 𝑜𝑛𝑙𝑦 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑡𝑒𝑐ℎ𝑛𝑖𝑐𝑎𝑙 𝑒𝑥𝑝𝑒𝑟𝑡𝑖𝑠𝑒 𝑎𝑛𝑑 𝑒𝑥𝑡𝑒𝑛𝑠𝑖𝑣𝑒 𝑒𝑥𝑝𝑒𝑟𝑖𝑒𝑛𝑐𝑒 𝑖𝑛 𝑖𝑚𝑚𝑢𝑛𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦 𝑏𝑢𝑡 𝑎𝑙𝑠𝑜 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑣𝑒 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑎𝑛𝑑 𝑠ℎ𝑎𝑟𝑒𝑑 𝑣𝑎𝑙𝑢𝑒𝑠. 𝐴𝑑𝑑𝑖𝑡𝑖𝑜𝑛𝑎𝑙𝑙𝑦, 𝑤𝑒 𝑣𝑎𝑙𝑢𝑒 𝑡ℎ𝑒𝑖𝑟 𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑡𝑜 𝑝𝑟𝑜𝑑𝑢𝑐𝑒 𝑜𝑢𝑟 𝑔𝑟𝑜𝑢𝑛𝑑𝑏𝑟𝑒𝑎𝑘𝑖𝑛𝑔 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑙𝑜𝑐𝑎𝑙𝑙𝑦 𝑖𝑛 𝐼𝑠𝑟𝑎𝑒𝑙, 𝑤ℎ𝑒𝑟𝑒 𝐻𝑜𝑝𝑒𝑐 𝑡𝑎𝑘𝑒𝑠 𝑝𝑟𝑖𝑑𝑒 𝑖𝑛 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑔 𝑎 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑡ℎ𝑎𝑡 𝑛𝑜𝑡 𝑜𝑛𝑙𝑦 𝑚𝑒𝑒𝑡𝑠 𝑡ℎ𝑒 ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑞𝑢𝑎𝑙𝑖𝑡𝑦 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠 𝑏𝑢𝑡 𝑎𝑙𝑠𝑜 𝑠ℎ𝑜𝑤𝑐𝑎𝑠𝑒𝑠 𝐼𝑠𝑟𝑎𝑒𝑙’𝑠 𝑔𝑙𝑜𝑏𝑎𝑙 𝑙𝑒𝑎𝑑𝑒𝑟𝑠ℎ𝑖𝑝 𝑖𝑛 𝑚𝑒𝑑𝑖𝑐𝑎𝑙 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛. 𝑊𝑒 𝑑𝑒𝑒𝑝𝑙𝑦 𝑎𝑝𝑝𝑟𝑒𝑐𝑖𝑎𝑡𝑒 𝑆𝑐𝑖𝑛𝑎𝑖'𝑠 𝑢𝑛𝑖𝑞𝑢𝑒 𝑏𝑙𝑒𝑛𝑑 𝑜𝑓 𝑝𝑟𝑜𝑓𝑒𝑠𝑠𝑖𝑜𝑛𝑎𝑙𝑖𝑠𝑚, 𝑝𝑎𝑠𝑠𝑖𝑜𝑛, 𝑎𝑛𝑑 𝑐𝑎𝑟𝑒, 𝑤ℎ𝑖𝑐ℎ 𝑚𝑎𝑘𝑒𝑠 𝑡ℎ𝑖𝑠 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑏𝑜𝑡ℎ 𝑠𝑒𝑎𝑚𝑙𝑒𝑠𝑠 𝑎𝑛𝑑 𝑖𝑛𝑠𝑝𝑖𝑟𝑖𝑛𝑔." commented Gadi Klarsfeld, Estee Rosen אסטי רוזן and Ilan Winkler from the Hopec leadership team. We at Scinai greatly appreciate Hopec’s commitment to disrupting decades-old treatment protocols with a therapy offering superior efficacy, fewer side effects, and improved accessibility.  🤝 Together, we are advancing a life-changing therapy that promises to improve patient outcomes and redefine the future of bladder cancer treatment on a global scale. Thank you Gadi Klarsfeld, Estee Rosen אסטי רוזן, Ilan Winkler and the Hopec Pharma team. Welcome to Scinai Immunotherapeutics Ltd. #CDMO #BioServices !   #Partnership #CDMO #Immunotherapy #Biotech #BladderCancer #Innovation #ScinaiImmunotherapeutics #HopecPharma #cGMP #CMC Elad Mark Tehila Sonnenfeld Amir Reichman Dalit Fischer

𝐖𝐞 𝐚𝐫𝐞 𝐡𝐨𝐧𝐨𝐫𝐞𝐝 𝐭𝐨 𝐰𝐞𝐥𝐜𝐨𝐦𝐞 𝐃𝐫. Jonathan Sadeh, M.D., M.Sc. 𝐟𝐨𝐫𝐦𝐞𝐫 𝐒𝐞𝐧𝐢𝐨𝐫 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐑&𝐃 𝐚𝐭 𝐁𝐫𝐢𝐬𝐭𝐨𝐥-𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛, 𝐭𝐨 Scinai Immunotherapeutics Ltd. 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐁𝐨𝐚𝐫𝐝 (𝐒𝐀𝐁)! Dr. Sadeh brings over 20 years of exceptional experience in drug development and clinical research, having spearheaded multiple drug approvals in fields such as dermatology, gastroenterology, and rheumatology. Most notably, he played a pivotal role in the approval of Sotyktu, a groundbreaking TYK2 inhibitor for the treatment of psoriasis. At Scinai, Dr. Sadeh will provide invaluable guidance as we advance our lead IL-17 program and our unique VHH antibody pipeline, leveraging his deep expertise to drive innovation in inflammation and immunology (I&I). Quoting Dr. Sadeh: "𝑆𝑐𝑖𝑛𝑎𝑖’𝑠 𝑢𝑠𝑒 𝑜𝑓 𝑉𝐻𝐻 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑖𝑒𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑎𝑛 𝑒𝑥𝑐𝑖𝑡𝑖𝑛𝑔 𝑜𝑝𝑝𝑜𝑟𝑡𝑢𝑛𝑖𝑡𝑦 𝑡𝑜 𝑎𝑑𝑑𝑟𝑒𝑠𝑠 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡 𝑢𝑛𝑚𝑒𝑡 𝑚𝑒𝑑𝑖𝑐𝑎𝑙 𝑛𝑒𝑒𝑑𝑠 𝑤𝑖𝑡ℎ 𝑎 𝑏𝑖𝑜-𝑏𝑒𝑡𝑡𝑒𝑟 𝑎𝑝𝑝𝑟𝑜𝑎𝑐ℎ. 𝐼’𝑚 𝑡ℎ𝑟𝑖𝑙𝑙𝑒𝑑 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑒 𝑡𝑜 𝑆𝑐𝑖𝑛𝑎𝑖’𝑠 𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑎𝑛𝑑 ℎ𝑒𝑙𝑝 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ 𝑖𝑡 𝑎𝑠 𝑎 𝑔𝑙𝑜𝑏𝑎𝑙 𝑙𝑒𝑎𝑑𝑒𝑟 𝑖𝑛 𝑠𝑐𝑖𝑒𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑙𝑙𝑦 𝑑𝑟𝑖𝑣𝑒𝑛 𝑑𝑟𝑢𝑔 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡." Welcome, Dr. Sadeh! We look forward to this transformative journey together. Follow the link to read the press release: https://lnkd.in/ejYSWXkh #Innovation #DrugDevelopment #Immunology #Biotech #Leadership #Scinai #Advisoryboard

𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 Scinai Immunotherapeutics Ltd. 𝐐𝟑 𝟐𝟎𝟐𝟒 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐫𝐞𝐬𝐮𝐥𝐭𝐬, 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐢𝐧𝐠 𝐚 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧𝐞𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧! 📍 A key highlight is the conversion of a €26.6 million loan from the European Investment Bank (EIB) into equity, 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐨𝐮𝐫 𝐬𝐡𝐚𝐫𝐞𝐡𝐨𝐥𝐝𝐞𝐫 𝐞𝐪𝐮𝐢𝐭𝐲 𝐟𝐫𝐨𝐦 𝐚 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 $𝟕.𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐬 𝐨𝐟 𝐉𝐮𝐧𝐞 𝟑𝟎, 𝟐𝟎𝟐𝟒, 𝐭𝐨 𝐚 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 $𝟏𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧. This strategic move significantly enhances our financial stability and growth prospects. 𝐁̲𝐮̲𝐬̲𝐢̲𝐧̲𝐞̲𝐬̲𝐬̲ ̲𝐔̲𝐧̲𝐢̲𝐭̲𝐬̲ ̲𝐇̲𝐢̲𝐠̲𝐡̲𝐥̲𝐢̲𝐠̲𝐡̲𝐭̲𝐬̲:̲ 👉 𝑂𝑢𝑟 𝐶𝐷𝑀𝑂 𝑏𝑢𝑠𝑖𝑛𝑒𝑠𝑠 𝑢𝑛𝑖𝑡 𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑟𝑒𝑣𝑒𝑛𝑢𝑒𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑡𝑖𝑚𝑒, 𝑚𝑎𝑟𝑘𝑖𝑛𝑔 𝑎 𝑠𝑜𝑙𝑖𝑑 𝑒𝑎𝑟𝑙𝑦 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒. While 2024 revenues are expected to remain moderate, we are negotiating attractive contracts with several companies. Additionally, we received a $575K non-refundable grant from the Israeli Innovation Authority (IIA), with another grant application for $267K pending. As demand for specialized CDMO services grows, we are positioning ourselves as a key partner for early-stage biotech companies. 👉 𝑂𝑢𝑟 𝑅&𝐷 𝐵𝑢𝑠𝑖𝑛𝑒𝑠𝑠 𝑢𝑛𝑖𝑡 𝑐𝑜𝑛𝑡𝑖𝑛𝑢𝑒𝑑 𝑡𝑜 𝑎𝑑𝑣𝑎𝑛𝑐𝑒 𝑜𝑢𝑟 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑝𝑖𝑝𝑒𝑙𝑖𝑛𝑒, 𝑝𝑢𝑏𝑙𝑖𝑠ℎ𝑖𝑛𝑔 𝑝𝑟𝑜𝑚𝑖𝑠𝑖𝑛𝑔 𝑝𝑟𝑒-𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑝𝑟𝑜𝑜𝑓 𝑜𝑓 𝑐𝑜𝑛𝑐𝑒𝑝𝑡 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑎𝑛𝑑 𝑟𝑒𝑐𝑒𝑖𝑣𝑖𝑛𝑔 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑓𝑒𝑒𝑑𝑏𝑎𝑐𝑘 from the Paul Ehrlich Institute for our planned clinical trials in plaque psoriasis. We are actively pursuing partnership opportunities for our anti-IL-17A/F nanoAb for plaque psoriasis and our additional, novel pipeline nanoAbs, all of this while exploring strategic licensing agreements to expand our pipeline. These positive developments in both our financial positioning and operational growth demonstrate our commitment to strengthening our foundation and delivering value to our shareholders and partners. 👉👉 For more details, view the full Q3 report: https://lnkd.in/diFQEVEk #FinancialResults #Q3 #Growth #Innovation #TeamSuccess #Biotech #BioPharma #NASDAQ  Amir Reichman

𝐓𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐚 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧 𝐚𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐬𝐞𝐭𝐭𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐬 𝐚 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐦𝐢𝐧𝐝𝐬𝐞𝐭 𝐬𝐡𝐢𝐟𝐭. 📍 While academic research often emphasizes exploration, the pharmaceutical industry prioritizes practical outcomes and scalability. 📍 Successful drug development demands agility, precision, and speed at every stage. It’s crucial to think ahead and plan for large-scale production from the very beginning, even when working on small-scale processes. 👉 For example: 𝐸𝑛𝑠𝑢𝑟𝑒 𝑡ℎ𝑎𝑡 𝑡ℎ𝑒 𝑟𝑎𝑤 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙𝑠 𝑢𝑠𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑎𝑟𝑙𝑦 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑎𝑟𝑒 𝑛𝑜𝑡 𝑜𝑛𝑙𝑦 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑏𝑢𝑡 𝑎𝑙𝑠𝑜 𝑚𝑒𝑒𝑡 𝑡ℎ𝑒 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑜𝑟 𝑦𝑜𝑢𝑟 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑎𝑔𝑒. 𝑂𝑣𝑒𝑟𝑙𝑜𝑜𝑘𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑐𝑎𝑛 𝑙𝑒𝑎𝑑 𝑡𝑜 𝑐𝑜𝑠𝑡𝑙𝑦 𝑑𝑒𝑙𝑎𝑦𝑠 𝑎𝑛𝑑 𝑠𝑒𝑡𝑏𝑎𝑐𝑘𝑠 𝑙𝑎𝑡𝑒𝑟 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠. 👇Check out below some valuable insights and recommendations from Dr. Dalit Fischer, CTO of Scinai Immunotherapeutics Ltd.! 👉👉 Explore our eBook, ‘A User’s Guide to Drug Development ‘, for more practical insights and expert guidance. Discover actionable strategies for navigating the complexities of bringing a drug to market. >> https://lnkd.in/dT98zPad #DrugDevelopment #PharmaInsights #Innovation #CDMO #MoleculeSelection #ExpertInsights #Biotech Amir Reichman Elad Mark Tamar Ben-Yedidia Dalit Fischer

#MeetTheExpert In our "Meet the Expert" series we are proud to spotlight Zohar Gadri, MSc, who heads the Process Development and Optimization efforts at Scinai Immunotherapeutics Ltd.. Working with Scinai for 13 years, Zohar specializes in protein purification, transitioning processes from laboratory settings to GMP-compliant production. 𝐙𝐨𝐡𝐚𝐫 𝐬𝐡𝐚𝐫𝐞𝐬 𝐡𝐢𝐬 𝐩𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐦𝐢𝐜𝐫𝐨𝐨𝐫𝐠𝐚𝐧𝐢𝐬𝐦 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐛𝐢𝐨𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:  "𝐶ℎ𝑜𝑜𝑠𝑖𝑛𝑔 𝑡ℎ𝑒 𝑟𝑖𝑔ℎ𝑡 𝑚𝑖𝑐𝑟𝑜𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚 𝑓𝑜𝑟 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑠 𝑛𝑜𝑡 𝑗𝑢𝑠𝑡 𝑎𝑏𝑜𝑢𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦; 𝑖𝑡'𝑠 𝑎𝑏𝑜𝑢𝑡 𝑏𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝑎 𝑓𝑜𝑢𝑛𝑑𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑠𝑐𝑎𝑙𝑎𝑏𝑙𝑒 𝑎𝑛𝑑 𝑠𝑢𝑠𝑡𝑎𝑖𝑛𝑎𝑏𝑙𝑒 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑠," he explains. 𝐇𝐢𝐬 𝐤𝐞𝐲 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐦𝐢𝐜𝐫𝐨𝐨𝐫𝐠𝐚𝐧𝐢𝐬𝐦 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: - Substrate Utilization: "Selecting a microorganism that efficiently utilizes substrates not only maximizes production but also reduces costs." - Genetic Stability: "A stable genetic makeup ensures consistent output and quality over time, crucial for regulatory compliance." - Production Efficacy: "Optimal microorganisms should demonstrate high production efficacy under varying operational conditions, enhancing scalability." He also emphasizes the strategic approach needed in biopharmaceutical manufacturing, "𝐼𝑡’𝑠 𝑐𝑟𝑢𝑐𝑖𝑎𝑙 𝑡𝑜 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟 𝑡ℎ𝑒 𝑓𝑢𝑙𝑙 𝑙𝑖𝑓𝑒𝑐𝑦𝑐𝑙𝑒 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑜𝑢𝑡𝑠𝑒𝑡. 𝑂𝑝𝑡𝑖𝑚𝑖𝑧𝑖𝑛𝑔 𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑎𝑙 ℎ𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑏𝑒𝑡𝑡𝑒𝑟 𝑦𝑖𝑒𝑙𝑑 𝑎𝑛𝑑 𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑐𝑎𝑛 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡𝑙𝑦 𝑒𝑛ℎ𝑎𝑛𝑐𝑒 𝑡ℎ𝑒 𝑑𝑜𝑤𝑛𝑠𝑡𝑟𝑒𝑎𝑚 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑖𝑛𝑔 𝑎𝑛𝑑 𝑜𝑣𝑒𝑟𝑎𝑙𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑒𝑓𝑓𝑖𝑐𝑎𝑐𝑦." 𝐙𝐨𝐡𝐚𝐫'𝐬 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐞𝐧𝐬𝐮𝐫𝐞𝐬 𝐭𝐡𝐚𝐭 𝐒𝐜𝐢𝐧𝐚𝐢'𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬 𝐚𝐫𝐞 𝐫𝐨𝐛𝐮𝐬𝐭 𝐚𝐧𝐝 𝐜𝐚𝐩𝐚𝐛𝐥𝐞 𝐨𝐟 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐝𝐞𝐦𝐚𝐧𝐝𝐬 𝐨𝐟 𝐦𝐨𝐝𝐞𝐫𝐧 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭. 𝐇𝐢𝐬 𝐰𝐨𝐫𝐤 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐨𝐮𝐫 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝐢𝐧 𝐜𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬. Stay tuned for more expert insights from the Scinai team! #Biopharmaceuticals #ProteinProduction #Biotechnology #ProcessDevelopment #InnovationInBiotech #DrugDevelopment #ExpertInsights #ProcessOptimization #GMPProduction #Scalability #MicroorganismSelection #Bioproduction #BiotechExcellence